These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
437 related articles for article (PubMed ID: 28678552)
1. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation. Mohammad D; Chan P; Bradley J; Lanctôt K; Herrmann N Expert Opin Drug Saf; 2017 Sep; 16(9):1009-1019. PubMed ID: 28678552 [TBL] [Abstract][Full Text] [Related]
2. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621 [TBL] [Abstract][Full Text] [Related]
3. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. Cooke JR; Loredo JS; Liu L; Marler M; Corey-Bloom J; Fiorentino L; Harrison T; Ancoli-Israel S Drugs Aging; 2006; 23(6):503-11. PubMed ID: 16872233 [TBL] [Abstract][Full Text] [Related]
4. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253 [TBL] [Abstract][Full Text] [Related]
5. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866 [TBL] [Abstract][Full Text] [Related]
6. Drugs for cognitive loss and dementia. Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314 [TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693 [TBL] [Abstract][Full Text] [Related]
8. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis. Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338 [TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors in the treatment of dementia. Ellis JM J Am Osteopath Assoc; 2005 Mar; 105(3):145-58. PubMed ID: 15863734 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Alzheimer's disease in the long-term-care setting. Smith DA Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308 [TBL] [Abstract][Full Text] [Related]
12. Effects of washout and dose-escalation periods on the efficacy, safety, and tolerability of galantamine in patients previously treated with donepezil: ongoing clinical trials. Rasmusen L; Yan B; Robillard A; Dunbar F Clin Ther; 2001; 23 Suppl A():A25-30. PubMed ID: 11396868 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine. Farlow MR Clin Ther; 2001; 23 Suppl A():A13-24. PubMed ID: 11396867 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990 [TBL] [Abstract][Full Text] [Related]
15. Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial. Campbell NL; Perkins AJ; Gao S; Skaar TC; Li L; Hendrie HC; Fowler N; Callahan CM; Boustani MA J Am Geriatr Soc; 2017 Jul; 65(7):1497-1504. PubMed ID: 28295141 [TBL] [Abstract][Full Text] [Related]
16. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease. Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552 [TBL] [Abstract][Full Text] [Related]
17. Effects of Acetylcholinesterase Inhibitors on Nutritional Status in Elderly Patients with Dementia: A 6-month Follow-up Study. Soysal P; Isik AT J Nutr Health Aging; 2016 Apr; 20(4):398-403. PubMed ID: 26999239 [TBL] [Abstract][Full Text] [Related]
18. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Inglis F Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367 [TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Lockhart IA; Mitchell SA; Kelly S Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314 [TBL] [Abstract][Full Text] [Related]